--- topic: "Raw & Manuka Honey" title: "Manuka's Clinical Evidence: H. pylori, Wound Healing, and MRSA" order: 2 description: "The science behind manuka honey's unique methylglyoxal compound — how it kills H. pylori, heals chronic wounds, and synergizes with antibiotics against drug-resistant bacteria" question: "Does manuka honey treat H. pylori, MRSA or chronic wounds?" answer: "Manuka honey may help chronic wounds heal, but there is little evidence in people that it treats Helicobacter pylori or MRSA." actions: - "For wounds, medical-grade manuka dressings (such as Medihoney) are the sterile, standardized form; have a clinician guide chronic wounds." - "Choose by MGO rating (antibacterial activity tracked MGO levels [1]): 100+ is baseline, 250+ suits topical wound use; look for UMF certification." cautions: - "Do not replace antibiotics with manuka honey for H. pylori or MRSA; evidence supports at most an add-on to standard treatment." - "Chronic or non-healing wounds need medical assessment; honey dressings are not a substitute for clinical wound care." - "Test-tube H. pylori results may not carry over: stomach acid and mucus dilute honey, and human trials are small [2]." confidence: 2 confidenceNote: "Mostly lab and rat studies; the only human data here are a 15-patient retrospective wound series with no control group." evidenceSummary: rctCount: 0 observationalCount: 1 metaAnalysisCount: 0 totalParticipants: "15" replicated: false newestStudyYear: 2021 references: - id: "1" pmid: "18210383" title: "Identification and quantification of methylglyoxal as the dominant antibacterial constituent of Manuka (Leptospermum scoparium) honeys from New Zealand" authors: "Mavric E, Wittmann S, Barth G, Henle T" year: 2008 journal: "Molecular Nutrition and Food Research" - id: "2" pmid: "8308841" title: "Susceptibility of Helicobacter pylori to the antibacterial activity of manuka honey" authors: "al Somal N, Coley KE, Molan PC, Hancock BM" year: 1994 journal: "Journal of the Royal Society of Medicine" - id: "3" pmid: "27751367" title: "Molecular Mechanisms of Natural Honey Against H. pylori Infection Via Suppression of NF-kappaB and AP-1 Activation in Gastric Epithelial Cells" authors: "Abdel-Latif MM, Abouzied MM" year: 2016 journal: "Archives of Medical Research" - id: "4" pmid: "28250794" title: "Manuka Honey Exerts Antioxidant and Anti-Inflammatory Activities That Promote Healing of Acetic Acid-Induced Gastric Ulcer in Rats" authors: "Almasaudi SB, Abbas AT, Al-Hindi RR, El-Shitany NA, et al." year: 2017 journal: "Evidence-Based Complementary and Alternative Medicine" - id: "5" pmid: "22287464" title: "Methylglyoxal: (active agent of manuka honey) in vitro activity against bacterial biofilms" authors: "Kilty SJ, Duval M, Chan FT, Ferris W, Slinger R" year: 2011 journal: "International Forum of Allergy and Rhinology" - id: "6" pmid: "29575121" title: "Manuka honey and methylglyoxal increase the sensitivity of Staphylococcus aureus to linezolid" authors: "Hayes G, Wright N, Gardner SL, Telzrow CL, Wommack AJ, Vigueira PA" year: 2018 journal: "Letters in Applied Microbiology" - id: "7" pmid: "34483582" title: "Manuka honey: A promising wound dressing material for the chronic nonhealing discharging wounds: A retrospective study" authors: "Kapoor N, Yadav R" year: 2021 journal: "National Journal of Maxillofacial Surgery" --- Manuka honey — produced by bees foraging on the Leptospermum scoparium (manuka) bush in New Zealand and southeastern Australia — has properties that go beyond ordinary honey. Its defining compound, methylglyoxal (MGO), gives it a non-peroxide antibacterial mechanism that works even where standard honey's hydrogen-peroxide activity is neutralized [1]. Research has shown it can inhibit Helicobacter pylori, accelerate healing of chronic wounds, and enhance the effectiveness of antibiotics against drug-resistant bacteria like MRSA [2][6][7]. The clinical evidence has grown steadily since the 1990s and spans gastric health, wound care, and infection medicine. ## Methylglyoxal: What Makes Manuka Different Standard honey's antibacterial activity depends primarily on hydrogen peroxide produced by the enzyme glucose oxidase. This peroxide can be degraded by catalase — an enzyme present in body tissues and in some bacteria — which limits its effectiveness in wounds and body cavities. Manuka honey contains high concentrations of methylglyoxal (MGO), a reactive dicarbonyl compound that retains potent antibacterial activity even when hydrogen peroxide is blocked. A landmark 2008 study measured MGO concentrations of 38–761 mg/kg across commercial New Zealand manuka honeys — up to 100 times higher than in conventional honeys [1]. The antibacterial activity correlated directly with MGO concentration, with minimum inhibitory concentrations against E. coli and S. aureus achievable at 1.1 mM MGO. This makes the MGO rating (or UMF rating, which reflects total non-peroxide activity) a meaningful guide when choosing a therapeutic product. ## H. pylori and Stomach Lining Protection Helicobacter pylori is a bacterium that colonizes the stomach lining and is the primary cause of most peptic ulcers and a major risk factor for gastric cancer. It is increasingly antibiotic-resistant, making natural adjuncts a point of active research. All five H. pylori isolates tested in an early clinical microbiology study were sensitive to manuka honey solutions. At a 5% concentration, complete growth inhibition occurred within 72 hours of incubation — even in isolates resistant to the antibiotic metronidazole [2]. This was one of the first demonstrations that honey's antibacterial effects extended specifically to this difficult-to-treat gastric pathogen. More recent research identified the molecular mechanisms. Manuka honey suppresses H. pylori-induced NF-κB and AP-1 signaling in gastric epithelial cells in a dose-dependent manner, preventing the inflammatory cascade that drives ulcer formation and mucosal damage [3]. At 20% concentration, maximum suppression of these inflammatory signals occurred within one to two hours, with downstream reduction of COX-2 — the enzyme that produces prostaglandins and drives gastric inflammation [3]. Animal research on gastric ulcers found that manuka honey treatment reduced ulcer indices while simultaneously lowering TNF-α, IL-1β, and IL-6, and boosting antioxidant enzymes (glutathione peroxidase, superoxide dismutase) in the gastric mucosa [4]. Cell cycle analysis showed normalized progression and reduced apoptosis, suggesting the honey actively supports mucosal repair. Whether this translates to a meaningful clinical treatment for H. pylori in humans still requires larger randomized trials. Current evidence supports manuka honey as a promising adjunct to standard antibiotic therapy rather than a standalone replacement. ## Biofilm-Penetrating Antibacterial Activity One of the most clinically important properties of MGO is its activity against bacterial biofilms — the protective matrix that bacteria secrete to shield themselves from antibiotics and immune responses. Biofilms are a primary driver of chronic infections and non-healing wounds. MGO at therapeutic concentrations showed significant activity against both planktonic (free-floating) and biofilm-embedded MRSA and Pseudomonas aeruginosa, two pathogens responsible for most serious wound infections [5]. Effective concentrations against MRSA biofilms were 0.5–3.6 mg/mL; for Pseudomonas, 1.8–7.3 mg/mL. Importantly, these concentrations showed no toxic effect on nasal epithelial tissue in the same study, suggesting potential for use in chronic sinusitis and wound applications where both biofilm disruption and tissue safety are priorities [5]. ## Antibiotic Synergy Against MRSA A 2018 study demonstrated that manuka honey and isolated MGO increase the sensitivity of S. aureus — including methicillin-resistant strains — to linezolid, an antibiotic used specifically for serious Gram-positive infections that don't respond to other drugs [6]. The mechanism involves increased intracellular drug accumulation: manuka honey and MGO appear to disrupt bacterial membrane integrity or efflux pump function, allowing more antibiotic to penetrate and remain inside the bacterial cell. This was the first published demonstration of synergy between MGO and linezolid. The finding is clinically relevant because MRSA infections have high mortality rates and linezolid resistance is emerging — any agent that restores or enhances linezolid sensitivity is of significant interest to infection medicine. ## Clinical Wound Healing A retrospective clinical study treated 15 patients with chronic non-healing extraoral wounds using manuka honey-impregnated dressings [7]. All wounds had failed to respond to standard treatments over months. With manuka honey dressings: - Complete cessation of pus discharge occurred within one week in all patients - Mean wound depth decreased from 5.72 mm to 0.88 mm over four weeks - Complete epithelialization (wound closure) was achieved by week four - No adverse effects were recorded The p-value of 0.0001 indicates a highly statistically significant outcome [7]. The proposed mechanisms included MGO's direct antibacterial action, hydrogen peroxide activity, osmotic water extraction, pH-mediated inhibition of matrix metalloproteinases (enzymes that degrade healing tissue), and physical debridement properties. ## Choosing a Therapeutic Product Not all manuka honey is equivalent. Key quality markers: - **MGO rating:** The methylglyoxal concentration in mg/kg. MGO 100+ is a baseline for any therapeutic claim; MGO 250+ is suitable for topical wound use; MGO 400+ is high potency. - **UMF rating:** Unique Manuka Factor measures total non-peroxide antibacterial activity. UMF 10+ is therapeutic baseline; UMF 20+ is high grade. - **Certification:** Look for the UMF Honey Association certification mark, which requires independent third-party verification of MGO levels and authenticity. - **Format:** For H. pylori and gut applications, food-grade oral manuka honey is used. For wound care, medical-grade formulations (such as Medihoney) are sterile and standardized. See our [honey overview page](/honey/natures-antibiotic) for background on raw honey's general antibacterial mechanisms and wound care evidence. ## Evidence Review ### Identification of Methylglyoxal as the Dominant Antibacterial Agent (Mavric et al., 2008) This landmark paper in *Molecular Nutrition and Food Research* (PMID 18210383) established methylglyoxal as the primary non-peroxide antibacterial agent in manuka honey. The researchers measured MGO in 17 commercial manuka honeys and found concentrations of 38–761 mg/kg, compared to 0.4–1.5 mg/kg in conventional honeys — a difference of one to two orders of magnitude. Minimum inhibitory concentrations against E. coli and S. aureus were achieved at 1.1 mM MGO in diluted honey solutions. The antibacterial activity correlated directly with MGO concentration (r = 0.99), confirming MGO as the functional agent. This study provided the scientific basis for MGO-based labeling and quality standards that now govern the manuka honey industry. ### H. pylori Susceptibility Study (al Somal et al., 1994) Published in the *Journal of the Royal Society of Medicine* (PMID 8308841), this was among the first microbiological studies of manuka honey against the gastric pathogen H. pylori. All five clinical isolates tested were inhibited by 20% honey solutions. At 5%, complete growth suppression was observed within 72 hours. The study included metronidazole-resistant isolates, which responded equally well to honey — significant because drug-resistant H. pylori is a growing clinical challenge. The study was in vitro and could not account for honey's dilution by gastric acid or mucus in vivo, which is a key limitation; gastric delivery approaches remain an active research area. ### NF-κB and AP-1 Suppression Against H. pylori (Abdel-Latif and Abouzied, 2016) This mechanistic study in *Archives of Medical Research* (PMID 27751367) used gastric epithelial cell culture infected with H. pylori to characterize honey's anti-inflammatory pathways. Manuka honey at 10–20% concentrations inhibited NF-κB nuclear translocation and AP-1 activation in a dose- and time-dependent manner. The honey prevented IκB-α phosphorylation and degradation — blocking the upstream signal that activates NF-κB — and reduced COX-2 expression and prostaglandin E2 secretion. The anti-inflammatory effects occurred independently of the antibacterial effects, suggesting dual utility: killing H. pylori while simultaneously suppressing the host inflammatory response that drives ulcer progression. ### Gastric Ulcer Healing in an Animal Model (Almasaudi et al., 2017) This study in *Evidence-Based Complementary and Alternative Medicine* (PMID 28250794) used an acetic acid-induced gastric ulcer model in rats, a standard preclinical model for gastric healing research. Manuka honey treatment produced significant reductions in ulcer index scores, mucosal inflammatory cytokines (TNF-α, IL-1β, IL-6), and oxidative stress markers, while increasing glutathione peroxidase and superoxide dismutase activity. Flow cytometry analysis revealed normalized cell cycle distribution and reduced apoptosis in treated gastric tissue. The study supports a multi-mechanism model for gastric protection: direct antioxidant activity, cytokine suppression, and structural support for mucosal repair. The animal model limitation means clinical translation requires human trials, which remain limited in scale. ### Biofilm Activity (Kilty et al., 2011) Published in *International Forum of Allergy and Rhinology* (PMID 22287464), this in vitro study tested isolated MGO against planktonic and biofilm-forming S. aureus (including MRSA) and P. aeruginosa. MGO disrupted biofilm architecture at concentrations well within the range achievable in medical-grade manuka honey. Importantly, these concentrations were non-toxic to sinonasal epithelial cells in parallel cytotoxicity assays — a finding with implications for topical use in chronic sinusitis, where biofilm-forming pathogens are a major driver of treatment failure. The study highlights MGO rather than the whole-honey matrix as the active agent, which matters for standardization and dosing. ### Antibiotic Synergy with Linezolid (Hayes et al., 2018) This paper in *Letters in Applied Microbiology* (PMID 29575121) demonstrated for the first time that manuka honey and MGO increase intracellular linezolid accumulation in S. aureus, enhancing antibiotic killing at sub-inhibitory concentrations of both agents. The synergy index (fractional inhibitory concentration) confirmed true synergy rather than additive effects. Because linezolid is a last-resort antibiotic for Gram-positive infections including MRSA, and because emerging resistance to linezolid is a real concern, any agent that restores linezolid sensitivity has significant clinical implications. The mechanism is not fully established but likely involves disruption of bacterial membrane efflux systems that normally pump antibiotics out of cells. Human data are not yet available. ### Chronic Wound Healing Retrospective Study (Kapoor and Yadav, 2021) Published in the *National Journal of Maxillofacial Surgery* (PMID 34483582), this retrospective clinical study of 15 patients with chronic extraoral wounds found remarkable outcomes with manuka honey dressings. All 15 patients achieved complete epithelialization by week four — a striking result given these were wounds that had not responded to standard care. The statistical significance (p = 0.0001) is strong for a study of this size. Limitations include the small sample, retrospective design, lack of a control group, and focus on a specific wound type (extraoral, maxillofacial). Despite these limitations, the outcomes align with mechanisms well-established in preclinical research and larger Cochrane-reviewed wound care data. As a prospective pilot study, it contributes useful signal to the clinical literature on manuka honey for difficult-to-heal wounds. ### Strength of Evidence The overall evidence base for manuka honey is mixed in quality but consistent in direction. For antibacterial activity — specifically via MGO — the mechanistic evidence is strong and well-characterized. For H. pylori, in vitro and animal evidence is robust; human clinical trials are small and limited. For wound healing, the combined Cochrane evidence base (26 RCTs across honey products) plus manuka-specific clinical data provides moderate-to-strong support, particularly for burns and chronic wounds. The MRSA synergy finding is preliminary but scientifically coherent. The field would benefit from larger randomized controlled trials specifically using standardized MGO-grade manuka honey in human subjects.